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B cell stimulatory factor 1 (BSF-1, interleukin 4)' was originally characterized
as a molecule that stimulates the proliferation of anti-IgM-activated B cells (1),
and has subsequently been found to have a multiplicity of other biological effects,
many on cell lineages outside the B lymphocyte compartment. In addition to
inducing the expression of class II MHC molecules on resting B cells (2, 3) and
enhancing the secretion of IgE and IgGI by stimulated B cells (4, 5), BSF-1 also
stimulates the proliferation of factor-dependent cell lines of both T cell and
hematopoietic lineages (6-11), as well as stimulating proliferation of both acti-
vated Lyt-2+ (9, 10) and L3T4+ (9-11) subpopulations of normal T lymphocytes.
Using '25I-labeled recombinant murine BSF-1, we have recently reported the
presence o£ receptors for this lymphokine on a broad spectrum of cell lineages
(12). Ohara and Paul (13), using radiolabeled natural murine BSF-1, found a
similarly broad distribution. While this observation serves to corroborate the
demonstration of diverse activities mediated by murine BSF-1, it also points out
the likelihood that this list of activities may expand.
The recent cloning of the gene encoding human BSF-1 (14) has now enabled
us to extend our studies to the characterization and distribution of the BSF-1
receptor on human cells. Using yeast-derived recombinant human BSF-1 radio-
labeled with ' 251, we have shown that the human BSF-1 receptor is present not
only on in vitro cell lines of B, T, and hematopoietic lineages, but is also found
on fibroblasts and cells of epithelial and endothelial origin. In this paper we
report the kinetic and structural characterization of the BSF-1 receptor on both
Raji cells (a human B lymphoma) and on primary human gingival fibroblasts,
The similarity we observe between the BSF-1 receptor on these two different
human cell lineages further supports the notion that the ability of BSF-1 to
mediate a spectrum of biological events is not due to overt differences in the
receptor for this lymphokine on different cell types.
Materials and Methods
Cell Preparations. FDC-P2 (15) and CTLL-2 (16) were maintained as previously
described (6). All other cell lines were grown in RPMI-1640 containing 5-20% FCS and
antibiotics. Adherent cell lines were harvested by scraping, following a brief treatment
' Abbreviations used in this paper:
￿
BS', bis-(sulfosuccinimidyl)suberate; BSF-1, B cell stimulating
factor 1 ; GM-CSF, granulocyte/macrophage colony stimulating factor.
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with 0.5 mM EDTA when necessary to aid cell detachment. Human peripheral blood
mononuclear cells were prepared from leukocyte layers (Portland Red Cross, Portland,
OR) and stimulated with PHA (Gibco Laboratories, Grand Island, NY) for 48 h, as
previously described (17). Human gingival fibroblasts (kindly provided by Dr. R. C. Page,
University of Washington, Seattle, WA) were maintained in DMEM containing 10% FCS
and generally used between passages 9 and 10. For radioreceptor assays, cells were
harvested with 0.05% trypsin and 0.02% EDTA, seeded at 105 cells/well in 6-well plates,
and used when the cells had reached confluency (1 .5-2 X 105 cells/well) after a minimum
incubation time of 72 h.
Hormone Preparations.
￿
Human recombinant IL-2 and granulocyte colony-stimulating
factor (G-CSF) were expressed in yeast under the control of the alcohol dehydrogenase 2
promoter and purified from the yeast media to homogeneity by reversed-phase high
performance liquid chromatography according to methods previously described (18-20).
Recombinant murine BSF-1 and human granulocyte/macrophage CSF (GM-CSF) were
expressed in yeast and purified to homogeneity as previously described (12, 21). Recom-
binant human IL-la and IL-10 were expressed in E. coli and purified to homogeneity as
previously described (22). Nerve growth factor, fibroblast growth factor, and epidermal
growth factor were obtained from Bethesda Research Labs (Gaithersburg, MD). Human
follicle stimulating hormone, human luteinizing hormone, human thyroid stimulating
hormone, and human growth hormone were from Calbiochem-Behring (La Jolla, CA).
Recombinant Human BSF-1 Purification and Radiolabeling.
￿
Human BSF-1 cDNA was
cloned from a cDNA library made from RNA extracted from peripheral blood T
lymphocytes (purified by E-rosetting) activated for 18 h with PHA and PMA. The BSF-1
cDNA clone was isolated by hybridization with a synthetic oligonucleotide based on the
published cDNA sequence (14). The full-length cDNA was subcloned into a yeast expres-
sion vector that included pBR322 sequences, the Trpl gene of yeast for tryptophan
selection, the yeast 2 k origin of replication, the yeast alcohol dehydrogenase 2 (ADH2)
promoter and the a factor leader sequences to direct synthesis and secretion. The
expression plasmid was transformed into yeast strain 79 (a trpl-1, leu2-2) selecting the
Trp+ transformants. Cultures were grown in rich medium (I% yeast extract, 2% peptone,
1 % glucose) at 30'C until stationary phase, and cells were removed by centrifugation and
filtration. Recombinant BSF-1 was purified from the yeast supernatant after 10-fold
concentration on an Amicon hollow-fiber device followed by addition offour parts acetone
(-20°C) to six parts yeast supernatant on ice. The acetone precipitate was resuspended
in 50 mM Hepes, pH 7 .4, at 1 mg/ml and applied to S-Sepharose (Pharmacia Fine
Chemicals, Piscataway, NJ) at 20'C. Recombinant BSF-1 was eluted using a linear gradient
of LiCl (0-1 M) in 50 mM Hepes, pH 7.4. Fractions containing BSF-1 were applied
directly to a proRPC column (Pharmacia Fine Chemicals) before elution with a linear
gradient ofacetonitrile (0-100%) in 0.1 % trifluoroacetic acid. In some cases, S-Sepharose-
purified BSF-1 (0.5 mg in 50 mM Hepes, pH 7.4, 0.3 M LiCl) was treated with 1 .25 U of
N-glycanase (Genzyme Corp., Boston, MA) for 30 d at 4 ° C before purification by reversed-
phase fast protein liquid chromatography. Afterpurification, rBSF-1 concentrations were
determined by amino acid analysis, and activity was measured in a B cell proliferation
assay. The specific activity of purified recombinant human BSF-1 was 10' U/kg. For the
B cell assay of rBSF-1, human tonsillar B cells were purified by depletion of T cells by E-
rosetting followed by depletion ofgranulocytes and monocytes by Sephadex G10 filtration.
The resting B cells (>95% pure) were assayed for their proliferative response to rBSF-1
in the presence of submitogenic concentrations of goat F(ab')2 anti-human IgM, in a 72-
h assay with 105 cells cultured in 200 til RPMI and 10% FCS.
Both untreated and glycanase-treated human recombinant BSF-1 were radiolabeled
using the enzymobead radioiodination reagent (BioRad Laboratories, Richmond, CA),
essentially as previously described for murine recombinant GM-CSF (23). The specific
activities of both radiolabeled preparations were estimated to be 2-6 X 10'5 cpm/mmol,
based on determination of an initial protein concentration by amino acid analysis and on
a recovery of 40% from control experiments in which an aliquot of BSF-1 was spiked with478 CELL SURFACE HUMAN B CELL STIMULATORY FACTOR I RECEPTOR
'25I-labeled BSF-1 and put through the iodination protocol with omission of "'l, Bioactiv-
ity of 125I-BSF-1 was determined in the human B cell proliferation assay described above.
Binding Assays and Data Analysis. Binding assays were performed by a phthalate oil
separation method (24) essentially as described previously for murine '25I-GM-CSF (23).
Sodium azide (0.2%) was included in all binding assays to inhibit internalization and
degradation of '25I-BSF-1 by cells at 37°C . Adherent human gingival fibroblasts were
assayed by incubating confluent monolayers in six-well plates (prepared as described
above) with 1251-BSF-1 in 1 ml of RPMI-1640 containing 2% BSA, 20 mM Hepes buffer,
and 0.2% sodium azide, pH 7.2 (binding medium). Plates were incubated on a gyratory
shaker for either 1 h at 37'C or 2 h at VC, C, after which an aliquot of the supernatant in
each well was removed and counted in a gamma counter, and the monolayers were washed
rapidly once with 5 ml of binding medium and three times with 5 ml of PBS. After
incubation in 1 ml of trypsin-EDTA at 370 C for 15 min, cells were harvested and the
entire aliquot was counted in a gamma counter. The number of cells per well was
determined by harvesting and counting cells from control wells that had undergone the
same incubation and wash conditions in the absence of 1251-BSF-1 .
Association and dissociation kinetic experiments were conducted as previously described
(23). Binding data was also analyzed, as described elsewhere (23) .
Affinity Crosslinking. Crosslinking experiments with human 1251-BSF-1 to Raji cells
were performed as previously described for murine BSF-1 (12). For human gingival
fibroblasts, confluent monolayers of cells in 9-cm dishes were incubated with '25I-BSF-1
(1 .3 X 10-9 M) at 4 °C in 3 ml of binding medium both in the presence and absence of a
100-fold or greater molar excess of unlabeled BSF-1 . After 2 h the plates were washed
three times in ice-cold PBS, and 4 ml of 0.1 mg/ml bis-(sulfosuccinimidyl) suberate (BS3)
in PBS was added to each . After a 30-min incubation at 25'C, plates were again washed
three times with PBS and cells were harvested by scraping and centrifugation, after a 15-
min incubation at 37°C in 4 ml of 5 mM EDTA. Cells were then incubated in 50 Al
PBS/I% Triton containing 2 mM phenylmethylsulfonylfluoride, 10 AM pepstatin, 10 AM
leupeptin, 2 mM o-phenanthroline, and 2 mM EGTA for 30 min at 25 ° C, centrifuged at
12,000 g for 10 min, and the supernatants were retained.
SDS-PAGE.
￿
Samples were boiled for 3 min in sample buffer (0.06 M Tris-HCI, pH
6.8, 2% SDS, 10% glycerol, 5% 2-ME) and analyzed on 8, 10, or 10-20% gradient gels
according to the stacking gel procedure of Laemmli (25). Methyl [' 4C]-labeled molecular
markers: cytochrome C (M,, 12,300), lactoglobulin A (Mr, 18,367), carbonic anhydrase
(Mr, 31,000), ovalbumin (M,, 46,000), BSA (M,, 69,000), phosphorylase B (A, 97,400),
and myosin (M,, 200,000) were from New England Nuclear (Boston, MA). After electro-
phoresis, gels were stained with Coomassie blue (0.25% in 25% isopropanol, 10% acetic
acid), dried and then exposed to Kodak X-omat AR film at -70'C.
Results
Purification and Radiolabeling of Human BSF-1.
￿
Recombinant human BSF-1
was expressed in yeast, purified to apparent homogeneity as described in Mate-
rials and Methods, and iodinated to high specific activity with the enzymobead
radioiodination reagent. Fig. 1, lane a, shows an autoradiograph of an iodinated
recombinant human BSF-1 preparation, which exhibits a broad band of ^-60,000
Mr (average). Radiolabeled preparations of BSF-1 were calculated to have specific
activities in the range of 2-6 X 10' 5 cpm/mmol, based on protein concentrations
determined by amino acid analysis. Such preparations retained >50% of their
biological activity (as measured in a human B cell proliferation assay), and were
stable for at least 1 mo when stored at 4°C in medium containing 2% BSA and
0.2% sodium azide. Treatment of recombinant human BSF-1 with N-glycanase
resulted in the appearance of a major species after iodination (sp act, 2.5 X 10 ' 5PARK ET AL .
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FIGURE I . Characterization of human '25I-BSF-1 by SDS-PAGE.
Lane a, "5I-labeled recombinant BSF-1, sp act 3.2 X 10'5 cpm/mmole ;
and (b) '25I-labeled N-glycanase-treated BSF-I, sp act 2.5 X 10`5
cpm/mmole were boiled in sample buffer containing 2% SDS and 5%
2-ME, and 5,000 cpm were applied to a linear 10-20% gradient gel .
Electrophoresis and autoradiography were conducted as described
under Materialsand Methods .
cpm/mmol) of ^-15,000 M,. (Fig. 1, lane b) . The relative molecular mass of the
digested protein is similar to the molecular weight ofthe nonglycosylated protein
predicted from its cDNA sequence, and suggests that recombinant human BSF-
1 is extensively glycosylated by the yeast host, similar to that previously observed
with yeast-derived recombinant murine BSF-1 (12) .
Binding Characteristics of BSF-1 with Cell Surface Receptors .
￿
Binding studies
undertaken with the glycosylated form ofhuman BSF-1 showed that it exhibited
specific binding to the human B cell line, Raji (26) . Preliminary experiments
showed that binding was saturable and extremely rapid, requiring <30 min to
reach equilibrium at either 37 or 4°C . Fig. 2A illustrates the association kinetics
at 37°C of 1251-BSF-1 with Raji cells, showing that both the final equilibrium
amount of ligand bound to cells and the approach to equilibrium are dependent
on the initial concentration of 1251-BSF-1 in the medium . Although the initial
rate of binding is so rapid that it makes collection of data at early times difficult,
the best-fit single exponential time-dependency curves passing through the data
(27) are consistent with the presence of a single population of receptors on these
cells. The inset (Fig. 2B) shows a plot of the pseudo-first-order forward rate
constants determined from the curves in Fig . 2A relative to the initial concentra-
tion of 1251-BSF-1 in the medium . The data shown fit a straight line, as expected
for a biomolecular reaction, and generate values of 3.36 ± 0.43 X 10"/M-min
for the forward rate constant (the slope) and 0.22 ± 0.03/min for the reverse
rate constant (the intercept on the ordinate) .
Fig . 2B shows the dissociation of 1251-BSF-1 from Raji cells at 37°C, both in
medium alone, where a fraction of the receptors areoccupied, and in thepresence
of 1 .37 X 10-7 M unlabeled BSF-1, where almost all the receptors are occupied .
Under both conditions, a biphasic kinetic pattern was observed, very similar to
that shown previously for murine BSF-1 (12) . The dissociation rate constants of480 CELL SURFACE HUMAN B CELL STIMULATORY FACTOR 1 RECEPTOR
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FIGURE 2.
￿
Association anddissociation kinet-
ics of 1251-BSF-1 with Raji cells at 37°C. (A)
Raji cells (1 .33 X 107 cells/ml) were incubated
with 9.82 X 10-1° M (0), 3.15 X 10-1° M (O)
or 9.59 X 10-11 M (A) 1251-BSF-1 at 37°C. At
thetimes indicated, aliquots were removedand
assayed for binding as described in Materials
and Methods. Nonspecific binding was meas-
ured in the presence of a 100-fold molarexcess
of unlabeled BSF-1 at each concentration of
'251-BSF-1. The continuous curves passing
throughthedata were calculated from thebest-
fit parametervalues usinga single exponential
term (27). Infinite time bindingand association
rate constants foreach curvewere respectively:
", 2,237.4 ± 48.7 molecules/cell and 0.54 ±
0.08/M-min;O, 1,401.1 t 43.9 molecules/cell
and0.35± 0.06/M- min; A, 619.3 ± 12.8 mol-
ecules/cell and 0.23 ± 0.02/M-min. A plot of
the association rate constant calculated from
each curve versus the molar concentration of 12Sí-BSF-1 initially present in the medium is
shown in the inset (in B). (B) Raji cells (6.67 X
107 cells/ml) were incubated with 1251-BSF-1
(3.5 X 10-9 M) for 1 hat 37°C. The cells were
then divided, harvested by centrifugation, and
resuspended in either binding medium alone
(p) or binding medium containing 1.37 X 10-7
M unlabeled BSF-1 (/). The cells were main-
tained at 37°C, and aliquots were removed at
various times and assayed for binding.
the fast component were 7.6 ± 0.9 X 10-2/min in medium alone and 6.1 ± 0.8
X 10-'/min in the presence of excess unlabeled BSF-1, while in both cases the
rate constant ofthe slow component was <I0-2/min. Comparison of these rates
revealed no significant sensitivity to receptor occupancy, suggesting that BSF-1
receptors on Raji cells are noncooperative (28). Using the average value for the
fast component of 6.9 ± 1.6 X 10-2/min, a ratio ofthe forward and reverse rate
constants gives a range of values for the affinity constant ofradiolabeled BSF-1
for its receptor of 2.6-7.2 X 109/M. This range is likely to be somewhat low,
both because it does not take into account the slow componentofthe dissociation
kinetics and because the difficulties in accurately measuring the extremely rapid
initial rate of 1251-BSF-1 binding may in fact underestimate the forward rate
constant. This latter problem may also contribute to the somewhat higher value
for the reverse rate constant determined from the association kinetics experi-
ments.
Fig. 3 illustrates typical equilibrium binding data for 1251-BSF-1 to Raji cells
at 37'C (Fig.3A), as well as to adherent human gingival fibroblasts at 4°C (Fig.
3B). Scatchard analysis of the data yielded a straight line, indicative of a single
class of binding sites for BSF-1 on both cell types. Nonspecific binding was
extremely low (<0.1% of the total cpm added) and increased linearly with
increasing concentration. From the average of eight binding experiments, the
calculated apparent Ka of BSF-1 binding to Raji cells was 6.10 ± 2.15 X 109/M
with 2,160 ± 530 specific binding sites per cell. This Ka was in the same range0
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FIGURE 3.
￿
Equilibrium binding of "'I-BSF-
1 to human gingival fibroblasts and Raji cells.
Raji cells, 1.33 X 10' cells/ml (A) and human
gingival fibroblasts, 2.4 X 105 cells/well (B)
were incubated with various concentrations of 1251-BSF-1 (sp act 4.2 X 10'5cpm/mmol) for 1
h at 37°C and for 2 h at 4°C, respectively.
Binding was assayed as described in Materials
and Methods. Data are corrected for nonspe-
cific binding (2.1 X 10" and 1.9 X 1012 Mole_
cules/cell/M for A and B, respectively), meas-
ured in thepresence ofa200-fold molar excess
of unlabeled BSF-1. The insets show Scatchard
representations of specific binding replotted
from A and B. Curve fitting was done as de-
scribed in Materials and Methods.
FIGURE 4.
￿
Inhibition of '251-BSF-1 bindingto Raji cellsby
unlabeled BSF-1. Raji cells (1 .33 X 10' cells/ml) were incu-
bated with '251-BSF-1 (3.04 X 10-'9 M) andvaryingconcen-
trations of unlabeled BSF-1. Incubation was for 45 min at
37°C andbindingwas assayed as described in Materials and
Methods. The continuous curve passing through the data
was calculated from a one-site competitive inhibition equa-
tion usingaK, valuefor '251-BSF-1 of 8.2 X 109/M. All data
were corrected for nonspecific binding measured in the
presence of 1.9 X 10-8 M unlabeled BSF-1.
as that obtained by analysis ofassociation and dissociation kinetics (4.9 ± 2.3 X
109/M). Similar experiments carried out at 4°C showed an apparent Ka of 6.12
± 1.12 X 109/M with 1,670 ± 300 specific sites per cell, values that are not
significantly different than those obtained at 37°C. Binding ofBSF-1 to human
gingival fibroblasts also yielded similar values, with a calculated Ka of 1 .1 ± 0.1
X 10'0/M and 1,950 ± 70 specific sites per cell.
Fig. 4 shows the inhibition of binding of 1251-BSF-1 to Raji cells at 37'C by
unlabeled BSF-1 . The curve passing through the data was calculated with a
single-site competitive inhibition equation consistent with the presence ofa single
class of BSF-1 receptors (29), and yielded an inhibition constant of 1 .17 ± 0.10
X 10'°/M. This value is only slightly higher than the Ka of the radiolabeled
material as measured by equilibrium binding to Raji cells (6.10 ± 2.15 X 109/M),
supporting the use of iodinated BSF-1 as a valid probe for characterization of
receptor binding properties.482 CELL SURFACE HUMAN B CELL STIMULATORY FACTOR 1 RECEPTOR
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FIGURE 5. Specificity of 1251-BSF-1 binding to
Raji cells. Raji cells (1 .33 X 10' cells/ml) were
incubatedwith1251-BSF-1 (3.5 X 10"1° M) and the
following unlabeled proteins at the concentrations
indicated: a, none; b, recombinant human BSF-1,
2.6 X 10' M; c, recombinant murine BSF-1, 5 X
10-8 M; d, human IL-la, 5 X 10-' M; e, human
IL-10, 5 X 10-' M;f, human IL-2, 5 X 10' M; g,
recombinant human GM-CSF, 7.5 X 10-' M; h,
recombinant human G-CSF, 1.8 X 10-' M; i, epi-
dermal growth factor, 3
lug/ml ; j, fibroblast growth
factor, 1 ug/ml; k, nerve growth factor, 2 Iag/ml;
l, luteinizing hormone (human), 1 Ag/ml; m,
growth hormone (human), 1 .7 X 10-' M; n, thy-
roid-stimulating hormone, 1 ;Lg/ml;o, follicle-stim-
ulating hormone, 1 ug/ml. Concentrations of par-
a b c d e f g h i
￿
j
￿
k
￿
I m n o
￿
tially pure hormone preparations are given in mi
Inhibitor
￿
crograms per milliliter total protein. Incubation
was for 1 h at 37°C and binding was assayed as
described under Materials and Methods.
In addition, inhibition experiments with nonglycosylated human BSF-1 (N-
glycanase treated) yielded an inhibition constant indistinguishable from that of
the glycosylated form (data not shown). Equilibrium binding experiments also
showed the iodinated nonglycosylated BSF-1 to have a similar Ka (3.50 ± 0.55 X
109/M) to that of the glycosylated form. Consequently, this nonglycosylated
material wasjudged to be a suitable analogue to glycosylated BSF-1 for affinity
crosslinking experiments, inwhich its smaller, morehomogeneous size isadistinct
advantage (see below).
The specificity of human BSF-1 binding to Raji cells was assessed by testing a
numberofpurified lymphokines and otherpolypeptide hormones fortheir ability
to compete with '251-BSF-1 binding to its receptor (Fig. 5). When present in
concentrations that were 100-1,000-fold greater (on a molar basis) than that of
1251-BSF-1, human BSF-1 eliminated >95% of 1251-BSF-1 binding, while none
of the other molecules tested, including human IL-1, IL-2, GM-CSF, and G-
CSF, exhibited any ability to compete.
Cellular Distribution ofHuman BSF-1 Receptors.
￿
Cell lines ofhuman, monkey,
and mouse origin were examined for their ability to bind human '251-BSF-1
(Table I). In all cases, complete binding curves were done over a range of '25I-
BSF-1 concentrations, and receptor numbers per cell were generated by Scat-
chard analysis of the data. Reminiscent of the broad cellular distribution of
murine BSF-1 receptors, human BSF-1 was found to bind to cells of all human
lineages examined, including fibroblasts and epithelial cells. Human BSF-1 also
bound to both monkey lines tested, but not to any murine lines. Although
receptor levels varied over a 25-fold range, expression on most cells was ex-
tremely low. Two human T lymphoma lines, RPMI-8402 and JMB12, did not
exhibit detectable levels of BSF-1 receptor. Peripheral blood mononuclear cells
also express low receptor levels when resting, but appear to increase their
receptor numbers by about fivefold upon stimulation with PHA.
Affinity Crosslinking.
￿
Further characterization of the BSF-1 receptor on Raji
cells andhumangingival fibroblasts, both ofwhich express ^-2,000 receptors/cell,PARK ET AL.
TABLE I
Cellular Distribution ofHuman BSF-1 Receptors
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* Bindingexperiments were conductedas described in Fig. 3. With each cell line, Scatchard analysis
of at least twoseparate sets of bindingdata was performed. Allprimarycells and in vitro cell lines
areof human origin unless otherwiseindicated.
was carried out by affinity crosslinking. Radiolabeled nonglycosylated BSF-I (N-
glycanase treated) was bound to cells in the presence or absence of unlabeled
BSF-I and cells subsequently exposed to the bifunctional crosslinking reagent
BS', extracted with PBS/I% Triton containing a cocktail ofprotease inhibitors,
and the soluble fractions were analyzed by SDS-PAGE. Fig. 6 showsa SDS-PAGE
analysis, run under reducing conditions, of "5I-BSF-I crosslinked to Raji cells
and human gingival fibroblasts. One major crosslinked band was observed on
both cell types (Fig. 6, lanes b and d). Controls showed that no crosslinked species
were found in the absence ofcrosslinker (lane a) or in a sample containing excess
unlabeled BSF-I (Fig. 6, lane c). From crosslinking experiments run on both 8
Designation Characteristics BSF-1 bound*
molecules/cell
Primary cells
Peripheral blood mononuclear Resting 140 ± 110
cells PHA-activated 710 ± 260
Gingival fibroblasts 1,950 ± 70
Cell lines
Raji B lymphoma 2,280 ± 210
Daudi B lymphoma 2,585 ± 55
Cess B lymphoma 525 t 25
BMB B lymphoma 190 ± 30
ARH 77 B lymphoma 200 ± 30
RPMI-1788 B lymphoma 220 ± 50
NALM 6 Pre-B lymphoma 115 ± 15
Peer T leukemia 210 t 50
HSB2 T lymphoma 210 ± 10
Jurkat T lymphoma 115 ± 15
RPMI-8402 T lymphoma <10
JMB 12 T lymphoma <10
HL-60 Promyelocytic leukemia 125 t 45
U937 Monocytic tumor 640 t 30
KG-1 Myelogenous leukemia 475 ±235
SK HEP Hepatoma 570 t 270
HPT Pancreatic tumor 610 f 60
HBT Bladdercarcinoma 495± 55
Calu-6 Epithelial 565 ± 105
HeLa Epithelial 445 t 25
MLA Tleukemia (simian) 1,820 ± 120
CVI Kidney fibroblast (simian) 2,190
CTLL Tcell (murine) <10
FDC-P2 Bone marrow-derived (murine) <10
L cells Fibroblast (murine) <10484 CELL SURFACE HUMAN B CELL STIMULATORY FACTOR 1 RECEPTOR
FIGURE 6.
￿
Characterization of the human BSF-1 receptor by affinity
crosslinking . Lanes a-c : Raji cells (2.0 X 10') were incubated with '25I-
BSF-1 (3 X 10-9 M) both in the absence (a and b) and presence (c) of
unlabeled BSF-1 (1 .3 X 10' M) . Incubation was for 1 .5 h at 37°C,
and cells were then harvested, washed, and crosslinked and extracted
as described in Materials andMethods . Lane ashowsa control with no
crosslinker added . Lane d : human gingival fibroblasts (5 X 10 5
cells/plate) were incubated with '251-BSF-1 (1 .2 X 10-9 M) for 2 h at
4°C. Plates were washed and cells were crosslinked, harvested, and
extracted as described in Materialsand Methods . Aliquots correspond-
ing to 106 Raji cells or 7 .5 X 10 5 gingival fibroblasts were boiled for 3
min in sample buffer containing 2% SDS and 5% 2-ME, andsubjected
to electrophoresis on a 10% gel .
and 10% polyacrylamide gels, an average relative molecular mass for the cross-
linked species on both Raji cells and gingival fibroblasts was calculated to be
154,000± 5,000. After subtraction of BSF-1 (15,000 M,), the crosslinked species
would be a membrane protein ofM r 139,000± 5,000 .
Discussion
125 I-labeled recombinant human BSF-1 was used to examine the cellular
distribution of receptors for this lymphokine, as well as to further characterize
these receptors on both Raji cells, a human B lymphoma, and on primary human
gingival fibroblasts. Reminiscent of the broad cellular distribution previously
shown for BSF-1 receptors on murine cells (12, 13), BSF-1 receptors were found
on in vitro human cell linesof B, T, and hematopoietic lineages . This distribution
has now been further extended by the detection of BSF-1 receptorson a number
of adherent human cell lines of both epithelial and endothelial character, as well
as on primary gingival fibroblasts . Using ' 21I-labeled murine BSF-l, we have also
observed BSF-1 receptors on similar murine cell lines (L . Park, unpublished
data) . The low level of expression of BSF-1 receptors on human cells was
comparable to that seen on mouse cells, and stimulation of human peripheral
blood mononuclear cells with PHA resulted in an approximate fivefold increase
in BSF-1 receptor expression, similiar to the increased expression of BSF-1
receptors reported after activation of primary murine B andT cells (12, 13) .
Comparison of the binding characteristics of the yeast hyperglycosylated form
of BSF-1 (M,. 60,000) and the N-glycanase-treated, sugar-free form on Raji
cells showed no significant differences in kinetic parameters . This provides
evidence that the addition of carbohydrate to the BSF-1 molecule at natural
glycosylation sites does not alter the binding characteristics of human BSF-1 for
its receptor . This result is in agreement with results with murine BSF-1, wherePARK ET AL.
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very similar binding characteristics were obtained by us (12) usinga recombinant
yeast-derived hyperglycosylated species (M, 49,000), and by Ohara and Paul (13)
using natural BSF-1 (A 20,000).
Equilibrium binding of human BSF-1 to Raji cells and gingival fibroblasts
revealed no obvious differences between the receptors found on these cells.
Similarly, preliminary structural information on the BSF-I receptor obtained by
affinity crosslinking showed that both Raji cells and gingival fibroblasts exhibited
a crosslinked species having an average M, of 154,000, which would correspond
to a receptor subunit size of 139,000 Mr. The large size ofthe crosslinked species
was unexpected from our previous crosslinking data, which showed a receptor
size of ^-75,000 M, on a number of murine cell lines (12), and from similar
experiments by Ohara and Paul which showed a receptor size on murine spleen
cells of 60,000 M, (13). Several explanations for this discrepancy can be sug-
gested: (a) the BSF-1 receptor on human and mouse cells may differ by 60,000-
80,000 M,-. While human and murine BSF-1 exhibit considerable amino acid
sequence homology (14), they show complete species specificity in receptor
binding, suggesting that substantial differences might exist in receptor structure
between the two species. (b) A large difference in apparent receptor size could
be caused by species-specific differences in the posttranslational modification of
a similar protein core. (c) The BSF-1 receptor may be composed ofa complex of
two or more proteins, and human BSF-1 may crosslink to a different component
ofthe complex than murine BSF-I. (d ) Finally, the receptor size we observed
on murine cells may represent a proteolytically cleaved fragment of the native
receptor. In previous work with the murine GM-CSF receptor (23), we showed
that this receptor was acutely protease sensitive, and if extracted from cells in
the absence of a cocktail of protease inhibitors, it would be degraded from a
130,000 to a 70,000 M, form. Depending on the cell type involved, some
degradation could not be prevented even in the presence ofthe protease inhibitor
cocktail. We have used the same protease inhibitor cocktail forextractions during
crosslinking studies with both mouse and human BSF-1, however the murine
receptor may be more protease sensitive than the human receptor. We are
currently investigating the possibility that the native receptor on murine cells is
actually comparable in size to that on Raji cells and human gingival fibroblasts.
Although the diversity ofbiological activities attributable to BSF-1 is substan-
tial, they have thus far been limited to effects on cells of lymphoid or myeloid
origin. With the observation that BSF-1 is also capable of binding to fibroblasts,
this lymphokine may soon join the ranks of other regulatory molecules such as
interleukin 1 (30) and transforming growth factor /3 (31), the receptors for which
are expressedon a wide arrayofdifferent tissuesandwhich appear tobe involved
in a complex network ofbiological activities. Molecules such as interleukin 1, 0
interferon, transforming growth factor a, and tumor necrosis factor are known
to stimulate fibroblast growth (32, 33) and secretion ofprostaglandins, collagen-
ase, and collagen (34-36), and have recently been implicated in regulating the
release of cytokines from fibroblasts as well (37). Future studies on BSF-1 and
its receptor should clarify the role that this molecule may play in a complex486 CELL SURFACE HUMAN B CELL STIMULATORY FACTOR 1 RECEPTOR
regulatory system of cytokines that bridge hematopoietic, connective tissue, and
lymphoid compartments.
Summary
'25I-labeled recombinant human B cell stimulatory factor 1 (BSF-1) was used
to characterize receptors specific for this lymphokine on in vitro cell lines
representing human B, T, and hematopoietic lineages, as well as on adherent
cell lines of epithelial and endothelial origin, and on primary human gingival
fibroblasts. BSF-1 binding was extremely rapid and saturable at both 4 and
37°C, with a slow dissociation rate. On all human cell types examined, BSF-1
bound to a single class of high-affinity receptor (<3,000 receptors per cell) with
a Ka of 0.5-1.0 X 101°/M. Human BSF-1 also bound to cell lines of simian but
not murine origin. Comparison of kinetic characteristics obtained with a yeast-
derived hyperglycosylated form ofBSF-1 (M, 60,000) and N-glycanase-treated,
sugar-free BSF-1 (Mr 15,000) showed no significant differences. Among a panel
of lymphokines and growth hormones, only unlabeled human BSF-1 was able to
compete for the binding of 115I-labeled human BSF-1. Affinity crosslinking
experiments resulted in the identification on both Raji cells and on primary
human gingival fibroblasts ofa receptor subunit with an average Mr of 139,000.
These studies show that the BSF-1 receptor on human cells has an extremely
broad cellular distribution, while further supporting the notion that the ability
of BSF-1 to mediate a spectrum of biological activities cannot be accounted for
byovertdifferences in the receptor for this lymphokine ondifferentcell lineages.
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